– CNBC
NextCure Presents Preclinical Data On NC181, A Novel Therapeutic Candidate Targeting ApoE4, For The Treatment Of Alzheimer’s Disease
Data presented at the 2023 Cambridge Health Tech Institute's 2nd Annual Neurodegeneration Targets Conference in Boston, MA
In preclinical testing, NC181 demonstrated amyloid clearance, prevention of amyloid
